US · BGLC
BioNexus Gene Lab Corp.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Kuala Lumpur 59200
- Website
- bionexusgenelab.com
Price · as of 2024-12-31
$2.08
Market cap 4.89M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $54.68 | +2,530.49% |
| Intrinsic Value(DCF) | $11.32 | +444.57% |
| Graham-Dodd Method(GD) | $0.19 | -91.05% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $2.99 | $4.84 | |||
| 2019 | $0.00 | $10.38 | |||
| 2020 | $240.00 | $8,045.92 | $1,472,003.04 | $14.15 | $10,836.24 |
| 2021 | $213.60 | $1,046.59 | $4,395.98 | $7.67 | $13.05 |
| 2022 | $31.20 | $1,765.45 | $261.38 | $3.39 | $2.29 |
| 2023 | $7.72 | $3,591.50 | $16.74 | $0.00 | $3.07 |
| 2024 | $3.69 | $54.68 | $15.48 | $0.19 | $0.00 |
AI valuation
Our deep-learning model estimates BioNexus Gene Lab Corp.'s (BGLC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $54.68
- Current price
- $2.08
- AI upside
- +2,530.49%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$11.32
+444.57% upside
Graham-Dodd
$0.19
-91.05% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BGLC | BioNexus Gene Lab Corp. | $2.08 | 4.89M | +2,530% | +445% | -91% | — | -4.11 | 0.79 | 0.69 | -1.70 | — | 0.79 | 13.56% | -16.55% | -16.81% | -17.78% | -39.19% | -14.64% | 0.03 | -74.42 | 3.81 | 3.05 | 2.93 | -4118.00% | -266.00% | 2885.00% | -37.43% | -1.15 | -61.29% | 0.00% | 0.00% | 0.00% | -1.53 | -0.98 | 0.25 | 2.45 |
| ADVB | Advanced Biomed Inc. Comm… | $4.06 | 4.4M | — | — | — | — | -1690.19 | 0.05 | — | — | -7324.16 | 0.05 | 0.00% | — | — | -0.01% | 0.00% | 0.00% | 0.00 | — | 2.09 | 1.01 | — | 2308.00% | — | -9171.00% | -0.11% | 0.00 | -0.06% | 0.00% | 0.00% | 1690.13% | — | 14968.87 | — | -3.52 |
| APM | Aptorum Group Limited | $0.78 | 4.95M | +30,801% | — | — | — | -1.20 | 0.24 | — | -2.03 | -4.65 | 0.24 | 0.00% | — | — | -18.56% | -15.20% | -23.21% | 0.16 | -25.84 | 0.22 | 0.20 | -0.66 | 2581.00% | -10000.00% | -8459.00% | -23.24% | -0.27 | -4.77% | 0.00% | 0.00% | 0.00% | -2.00 | -6.39 | — | -6.61 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| GLTO | Galecto, Inc. | $29.58 | 47.25M | — | — | — | — | -0.22 | 0.30 | — | 0.45 | — | 0.30 | 0.00% | — | — | -89.03% | -3844.56% | -77.45% | 0.00 | — | 14.07 | 12.58 | 0.67 | -4864.00% | — | -4955.00% | -396.40% | -15.56 | -3216.41% | 0.00% | 0.00% | 0.00% | 0.42 | 0.50 | — | -23.70 |
| LFWD | Lifeward Ltd. | $7.40 | 11.28M | +6% | +25,985% | — | — | -0.49 | 0.75 | 0.55 | -0.32 | -1.71 | 1.25 | 32.01% | -76.19% | -112.78% | -88.56% | -118.09% | -61.79% | 0.05 | -152.76 | 2.08 | 1.27 | 0.24 | 2857.00% | 8524.00% | 468.00% | -153.36% | -2.12 | -131.16% | 0.00% | 0.00% | 0.00% | -0.41 | -0.37 | 0.32 | -12.27 |
| LYRA | Lyra Therapeutics, Inc. | $1.01 | 1.79M | +2,414% | +280% | — | — | -6.69 | 53.92 | 407.49 | -10.27 | -49.59 | 53.92 | 100.00% | -6280.83% | -6090.94% | -184.99% | -1017.13% | -89.43% | 2.97 | — | 3.41 | 3.21 | 0.10 | 1349.00% | -154.00% | 1243.00% | -11.57% | -5.54 | -763.78% | 0.00% | 0.00% | 1.72% | -6.42 | -8.55 | 403.45 | -5.91 |
| MBIO | Mustang Bio, Inc. | $1.01 | 7.37M | — | — | — | — | -0.58 | -2.34 | — | -0.21 | — | -2.34 | 0.00% | — | — | 840.11% | 241.62% | -116.47% | -0.23 | 3249.00 | 0.68 | 0.57 | 0.40 | -5717.00% | — | -7699.00% | -125.80% | -0.90 | 169.70% | 6.74% | -3.90% | 31.27% | -0.19 | -0.27 | — | -65.53 |
| TRIB | Trinity Biotech plc | $0.72 | 7.47M | +6,885% | -61% | — | — | -0.39 | -0.35 | 0.20 | -6.39 | — | -0.14 | 34.83% | -34.38% | -51.64% | 107.52% | -42.24% | -39.07% | -2.86 | -2.21 | 1.28 | 0.62 | -5.65 | -4469.00% | 831.00% | 1533.00% | -115.03% | -0.13 | -28.45% | 0.00% | 0.00% | 0.00% | -5.10 | -7.58 | 1.75 | -0.99 |
| XAIR | Beyond Air, Inc. | $0.96 | 4.87M | +6,086% | +58% | — | — | -0.27 | 0.95 | 3.47 | -0.42 | — | 1.04 | -44.89% | -1202.08% | -1258.43% | -250.98% | -332.73% | -111.42% | 0.86 | -14.75 | 3.20 | 1.56 | -0.17 | -6210.00% | 21967.00% | -2859.00% | -342.82% | -7.64 | -329.47% | 0.00% | 0.00% | 0.00% | -0.40 | -0.40 | 4.76 | -17.17 |
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
- CEO
- Su-Leng Tan
- Employees
- 30
- Beta
- 2.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($11.32 ÷ $2.08) − 1 = +444.57% (DCF, example).